Plasma Pregnancy-Associated Plasma Protein A and CD40 are Potential Biomarkers of Vulnerable Plaque Associated with Middle Cerebral Artery Stenosis

Xiujuan Wu, Jiarui Lu, Zhengzheng Wang, Yingqi Xing†, Kangding Liu†

Abstract

Intracranial artery stenosis, especially middle cerebral artery stenosis (MCAS), is prevalent in the Chinese population. Currently, few approaches target evaluating MCAS-associated plaque vulnerability. Herein we aimed to explore potential plasma biomarkers for vulnerable plaque in patients with MCAS. A total of 81 subjects who received microembolic signal (MES) detection were enrolled between September 2012 and September 2014. Of them, 19 patients did not have either acute ischemic infraction or cranial artery stenosis, 19 were patients with acute ischemic infraction whereas without any cranial artery stenosis, and the remaining 43 were patients with acute ischemic infraction caused by MCAS. Acute ischemic infraction (mean volume, $3.8 \pm 2.81 \text{ cm}^3$) was demonstrated by diffusion-weighted imaging in 30 patients. The acute infarction volume didn’t correlate with plasma concentrations of pregnancy-associated plasma protein A (PAPP-A), insulin-like growth factor 1, inducible nitric oxide synthase, lipoprotein-associated phospholipase A2, CD40, and CD40L ($P > 0.05$). The plasma PAPP-A (odds ratio [OR], 0.983; $P = 0.024$; 95% confidence interval [CI], 0.968–0.998), CD40 (OR, 1.063; $P = 0.015$; 95% CI, 1.012–1.117), and CD40L (OR, 0.867; $P = 0.015$; 95% CI, 0.773–0.972) concentrations severed as predictors for moderate to severe MCAS by multivariate logistic regression analysis. In addition, plasma PAPP-A (OR, 0.982; $P = 0.016$; 95% CI, 0.967–0.997) and CD40 (OR, 1.040; $P = 0.025$; 95% CI, 1.005–1.007) concentrations were also identified to be predictive for MES. In summary, plasma PAPP-A and CD40 might be potential biomarkers for vulnerable plaque associated with MCAS.

Keywords

Microembolic signal, Middle cerebral artery, Pregnancy-associated plasma protein A, CD40

Introduction

Stroke, one of the primary causes of morbidity and mortality worldwide, is a heterogeneous diseases caused by a variety of pathophysiological mechanisms. Cranial artery stenosis is an important risk factor for ischemic stroke. There are marked differences in the distribution of arterial lesions among different populations [1,2]. For example, intracranial artery stenosis is the predominant vascular lesion found in patients of Asian, African, or Hispanic ancestry; while extracranial artery stenosis is prevalent in white individuals. Artery-to-artery embolism due to the vulnerable plaque is one of the predominant mechanisms of ischemic infarction in patients with cranial artery stenosis. The
Subjects and Methods

Subjects

This study was approved by the ethics committee of The First Hospital of Jilin University. The experiment was conducted with the understanding and written informed consent was obtained from all patients. A total of 81 subjects who received MES detection were enrolled between September 2012 and September 2014. Of them, 19 patients did not have acute ischemic infraction or cranial artery stenosis, 19 were patients with acute ischemic infarction whereas without any cranial artery stenosis, and the remaining 43 were patients with acute ischemic infraction caused by MCAS. The acute ischemic infraction of the enrolled patients was in the MCA territory that occurred within 1 week. Of note was that patients with MCAS did not have any other intra- or extra-cranial artery stenosis. Patients were excluded if they met one of the following criteria: (1) presence of a poor temporal acoustic window; (2) could not consent to participate in the study (e.g. in an agitated or confused state); (3) had other potential sources of embolism, such as cardiogenic emboli and bloodborne emboli as well as any other artery borne embolic source; or (4) had an inflammatory or infectious disease or an autoimmune disorder. All of the enrolled patients with acute ischemic infraction did not receive heparin treatment or thrombolytic therapy.

All of the recruited patients underwent examinations including TCD, carotid duplex, and MES detection. The ischemic infraction was demonstrated by cranial MRI or computed tomography. The volume of the acute ischemic infraction of each diffusion-weighted imaging (DWI) lesion was calculated by two independent neuroradiologists who were blinded to the clinical data using Image J. All axial DWI lesion volumes were computed by multiplying the area of each slice by the section thickness. At baseline, demographic data including sex, age, and vascular risk factors including previous history of hypertension, diabetes mellitus (DM), ischemic heart disease, and smoking history were recorded for all patients. Hypertension, DM, and ischemic heart disease were diagnosed by cardiologists and diabetologists.

Diagnostic criteria of MCAS

The intracranial arteries were assessed by TCD (EME-TC8080; Nicolet, Germany) and the
extracranial arteries were assessed by carotid duplex (iU22; Philips, USA). Through the temporal window, the MCA-MI, anterior cerebral artery (ACA)-Al, posterior cerebral artery (PCA), and intracranial segment of the internal carotid artery (mainly the siphon and terminal segments) were detected by TCD using a 2 MHz probe; through the pillow window, the intracranial segment of internal carotid artery and the basilar artery were detected. The ophthalmic artery and the siphon segment of internal carotid artery were detected through the eye window. The criteria for the diagnosis of MCAS by TCD were based on the previously published criteria as follows [24-26]: mild stenosis was defined as a systolic peak velocity of 140–209 cm/s, moderate stenosis was 210–280 cm/s, and severe stenosis was >280 cm/s.

### MES detection

MES detection was performed by using two 2 MHz probes which were fixed on bilateral temporal window. The investigation depth of the affected MCA was located in the pre- and post-stenotic areas or the intra- and post-stenotic areas. The sample volumes were chosen to be as low as possible to avoid overlap, usually 8mm. In addition, the distance of the two investigation depths of the same vessel was greater than the sample volume. Emboli originating proximal to the MCAS passed through the different sample volumes, while emboli exiting from the MCAS would only pass the second channel located distal to the stenosis and produce a typical signal but no signal in the pre-stenotic sample volume. Therefore, an embolic signal would be recorded in the distal but not proximal sample volume. Artifacts simultaneously produce a typical pattern in both segments. The probe on the healthy side adopted the same settings as the affected side; gain and power were turned down as far as possible. In addition, all data were continuously recorded onto a four-channel digital audio tape recorder at normal speed. The recorded data were then analyzed by two experienced observers who were blinded to the clinical data. The number of MES during the 30-minute recording was noted. The following definitions for embolic signals were used: typical visible and audible (click, chirp, whistle) short-duration, high-intensity signal within the Doppler flow spectrum with its occurrence at random in the cardiac cycle, and an intensity increase of ≥5 dB above the background signal, and MES recorded from MCA stenoses has the special characteristic of multiple frequencies [27,28]. The spectrum of MES in patients with MCAS is illustrated in Figure 1.

### Plasma sample collection and enzyme-linked immunosorbent assay measurements

Plasma samples were collected by venous puncture at 7:00 a.m and then aliquoted and stored at -80°C until further enzyme-linked immunosorbent assay (ELISA) analysis. ELISA kits for the detection of PAPP-A (R&D Systems, Minneapolis, USA), IGF-1 (R&D Systems), iNOS (Elabsience Biotechnology, Wuhan, China), Lp-PLA2 (R&D Systems), CD40 (Abnova, Taibei, Taiwan), and CD40L (Abnova, Taibei, Taiwan) were purchased from their respective manufacturers. Each kit employed the quantitative sandwich enzyme immunoassay technique. The kits were used according to the manufacturers' instructions.

### Statistical Analysis

The statistical analysis was performed with SPSS version 17.0 software (IBM, West Grove, PA, USA). Categorical data are presented as proportions, while continuous data are presented as means and standard deviations or medians and interquartile ranges depending on the data distribution. Independent predictors were determined using multivariate logistic regression analysis using the variables with statistically significant contributions obtained on univariate analysis. For all statistical tests, values of $P < 0.05$ were considered significant.

### Results

#### Demographic features of enrolled patients

Among the 81 enrolled subjects, there were 19 subjects without ischemic infraction or cranial artery stenosis, 19 patients with acute ischemic infraction but without cranial artery stenosis, and 43 patients with symptomatic MCAS. The baseline demographics of all recruited patients are illustrated in Table 1. It was of note that the frequency of MES in healthy subjects and patients without cranial artery stenosis was both 0%; while it was 24/43 (55.8%) in patients with MCAS.

#### Acute ischemic infarction volume was negatively associated with plasma concentrations of different molecules

We further investigated the correlation between the acute ischemic infarction volume as demonstrated by DWI on MRI and the plasma
concentrations of PAPP-A, IGF-1, iNOS, Lp-PLA2, CD40, and CD40L. The acute ischemic infraction demonstrated by DWI was available for 30 patients. The mean volume of the acute ischemic infraction was $3.8 \pm 2.81$ cm$^3$. The mean plasma concentrations of PAPP-A, IGF-1, iNOS, Lp-PLA2, CD40, and CD40L of these 30 patients was $132.9 \pm 34.59$ pg/mL, $401.4 \pm 219.93$ µg/mL, $523.5 \pm 506.0$ pg/mL, $15.2 \pm 11.6$ µg/mL, $25.6 \pm 19.1$ µg/mL, and $9.7 \pm 0.6$ µg/mL, respectively. Correlation analysis revealed negative results between the acute ischemic infarction volume and the plasma concentrations of different molecules including PAPP-A, IGF-1, iNOS, Lp-PLA2, CD40, and CD40L ($P > 0.05$).

**Predictors for moderate to severe MCAS**

As artery stenosis is one of the major criteria for vulnerable plaque [3], we first explored the predictor for MCAS. Univariate analysis suggested that plasma PAPP-A (odds ratio [OR], 0.982; $P = 0.004$; 95% confidence interval [CI], 0.969–0.994), CD40 (OR, 1.055; $P = 0.016$; 95% CI, 1.010–1.102) and CD40L (OR, 0.881; $P = 0.012$; 95% CI, 0.799–0.973) were statistically significant variables, while the concentrations of IGF-1, iNOS, and Lp-PLA2 (all $P > 0.05$) were insignificantly different. Further, these statistically significant variables were confirmed by the multivariate analysis (Table 2). Thus, plasma PAPP-A, CD40, and CD40L were predictive for moderate to severe MCAS. The plasma concentrations of PAPP-A and CD40L were protective factors, while that of CD40 was a risk factor for MCAS.

**Plasma concentrations of PAPP-A and CD40 were predictors for presence of MES**

Since MES was predominantly found in patients
with acute ischemic infarction, especially those caused by moderate to severe MCAS [21], we further investigated the predictors for MES by using multivariate logistic regression analysis. Univariate analysis found that PAPP-A (OR, 0.985; \( P = 0.029; 95\% \text{ CI}, 0.972–0.999 \)), Lp-PLA2 (OR, 0.933; \( P = 0.04; 95\% \text{ CI}, 0.874–0.997 \)), and CD40 (OR, 1.042; \( P = 0.035; 95\% \text{ CI}, 1.003–1.083 \)) were significant variables, while plasma concentrations of IGF-1, iNOS, and CD40L (\( P > 0.05 \)) were insignificant variables. Based on the above findings, the final model for multivariate analysis identified that plasma concentrations of PAPP-A and CD40 were predictive for the presence of MES (Table 3). The plasma concentration of PAPP-A was a protective factor, while that of CD40 was a risk factor for MES.

**Discussion**

In this study, we found that the acute ischemic infarction volume was not related to the plasma concentrations of PAPP-A, IGF-1, iNOS, Lp-PLA2, CD40, and CD40L. However, plasma PAPP-A, CD40, and CD40L were predictors for moderate to severe MCAS, while PAPP-A and CD40 were predictive for presence of MES.

The concept of vulnerable plaque has been proposed as a paradigm to improve cardiovascular disease prevention and outcome, and the currently proposed definition criteria of vulnerable plaque includes active inflammation, a thin cap with a large lipid core, fissured cap, endothelial denudation, severe stenosis, or a combination thereof [3,29]. However, approaches for assessing the plaque vulnerability associated with intracranial artery stenosis were insufficient due to its location. Searching for the simple approach to vulnerable plaques evaluation in patients with MCAS is essential in the Chinese population. MES was mainly found in symptomatic patients with moderate to severe MCAS [23]. Moreover, patients with MES could predict the recurrent cerebral ischemic events

| Table 1: Demographic and clinical characteristic of the enrolled patients. |
|-----------------------------|-----------------------------|-----------------------------|
| Variables                   | Group 1 (N=19)              | Group 2 (N=19)              | Group 3 (N=43)              |
| Age (year-old)              | 56.62 ± 11.83               | 55.16 ± 11.53               | 57.58 ± 8.57                |
| Male to female ratio        | 16:3                       | 16:3                       | 36:7                       |
| Hypertension                | 12/19 (63.2%)               | 11/19 (57.9%)               | 27/43 (62.8%)               |
| Diabetes mellitus           | 4/19 (21.1%)               | 2/19 (10.6%)               | 8/43 (18.6%)               |
| Ischemic heart disease      | 4/19 (21.1%)               | 0 (0%)                     | 5/43 (11.6%)               |
| Smoking                     | 11/19 (57.9%)               | 4/19 (21.1%)               | 20/43 (46.5%)               |
| MES (%)                     | 0                          | 0                          | 24/43 (55.8%)               |
| PAPP-A (pg/ml)              | 130.1 ± 40.0               | 156.6 ± 43.9               | 118.5 ± 32.3               |
| IGF-1 (ug/ml)               | 433.8 ± 243.6              | 372.1 ± 215.3              | 461.1 ± 252.6              |
| iNOS (pg/ml)                | 521.7 ± 475.6              | 562.9 ± 510.6              | 503.5 ± 464.4              |
| Lp-PLA2 (ug/ml)             | 18.9 ± 12.8                | 16.3 ± 12.4                | 13.7 ± 9.0                |
| CD40 (ug/ml)                | 4.5 ± 12.9                 | 11.4 ± 12.8                | 23.0 ± 42.9                |
| CD40L (ug/ml)               | 12.7 ± 6.6                 | 11.5 ± 4.6                 | 9.1 ± 4.1                 |

Group 1: the healthy subjects; Group 2: acute ischemic infarction group without artery stenosis; Group 3: symptomatic middle cerebral artery stenosis (MCAS) group regardless of microembolic signal (MES); PAPP-A: pregnancy-associated plasma protein A; IGF-1: insulin-like growth factor 1; iNOS: inducible nitric oxide synthase; Lp-PLA2: lipoprotein-associated phospholipase A2

| Table 2: Plasma molecules related to moderate to severe middle cerebral artery stenosis. |
|-----------------------------|-----------------------------|-----------------------------|
| Variable                    | Regression coefficient (95% CI) | p-value | Exp (B) |
| PAPP-A                      | -0.017 (0.968-0.998)         | 0.024  | 0.983 |
| CD40                        | 0.061 (1.012-1.117)         | 0.015  | 1.063 |
| CD40L                       | -0.143 (0.773-0.972)        | 0.015  | 0.867 |

PAPP-A: pregnancy-associated plasma protein A

| Table 3: Plasma molecules associated with microembolic signal. |
|-----------------------------|-----------------------------|-----------------------------|
| Variable                    | Regression coefficient (95% CI) | p-value | Exp (B) |
| PAPP-A                      | -0.018 (0.967-0.997)         | 0.016  | 0.982 |
| CD40                        | 0.039 (1.005-1.077)         | 0.025  | 1.040 |

PAPP-A: pregnancy-associated plasma protein A
Research

Dr. Yingqi Xing

in patients with MCAS, implying that MES detection is a potential technique for evaluating plaque vulnerability [30]. However, MES detection has some limitations, and searching for the plasma biomarkers for vulnerable plaques is urgently needed. In the present study, we found that PAPP-A and CD40 were predictive for MES. However, due to the small sample size, the ability of plasma PAPP-A and CD40 to serve as plasma biomarkers for vulnerable MCAS-associated plaques requires validation in further studies with larger sample sizes.

PAPP-A, a high-molecular-weight, zinc-binding matrix metalloproteinase with an incompletely clear biological function, was first identified in the sera of pregnant women. To date, the clinical significance of PAPP-A has predominantly focused on gynecology and obstetrics. In 2001, PAPP-A was first evaluated in patients with ACS and proposed to be caused by vulnerable plaques [31]. Similar results were found in the study conducted by Heeschen and colleagues [32]. However, Heider and colleagues found that PAPP-A concentrations were slightly higher in asymptomatic than in symptomatic patients with carotid stenosis [33]. Other studies also demonstrated that patients with hyper- or isoechoic carotid plaques exhibit significantly higher PAPP-A levels than those with hypoechoic early carotid lesions [34]. These studies on the correlation between PAPP-A and carotid plaque indicated the possible protective role of PAPP-A in the development of vulnerable carotid plaque [33,34]. Collectively, the correlation between plasma PAPP-A concentration and vulnerable plaque from different studies remains controversial. In addition, PAPP-A could cleave IGF-binding proteins 4 and 5 and lower their affinity to IGF, after which free IGF interacts with its receptors. The binding of IGF to its receptors plays a role in atherosclerosis by increasing cholesterol uptake into plaques and increasing cytokine release [35]. However, IGF-1 also had favorable effects as its metabolic ability in coupling vasodilation has been suggested to play a key role in its anti-atherogenic function [36]. These contrasting effects keep the role of PAPP-A in atherosclerosis unclear. Here we found that plasma PAPP-A concentration but not IGF-1 was related to MES and moderate to severe MCAS. However, the mechanisms of the protective role of PAPP-A could not ascribe to the IGF-1 and remains unclear, which warrants further validation studies.

Plasma CD40, i.e. soluble CD40, is proteolytically cleaved from membrane-bound CD40, which could bind to CD154 and inhibit CD40–CD154-mediated immune responses. To our knowledge, the CD40–CD154 interaction plays a critical role in immunity and inflammatory regulation as well results in the production of numerous chemokines and cytokines, upregulation of adhesion molecules, secretion of matrix metalloproteinases, and induction of apoptosis [37]. Plasma CD40, serving as a CD40 antagonist, could bind to CD154, thereby inhibiting the CD40–CD154-mediated immune responses. Theoretically, plasma CD40 should be protective for vulnerable plaques by inhibiting active inflammation. In our study, however, we found that plasma CD40 was a risk factor for MES and moderate to severe MCAS, although its mechanism was unclear. Of note was that inflammatory markers differed between carotid and MCA atherosclerosis, and MCA atherosclerosis–associated plaques might be more stable than those associated with carotid atherosclerosis [38]. Thus, it is reasonable to speculate that the characterization of vulnerable MCAS-associated plaques might be also different from that related to carotid stenosis. However, this finding requires further study.

This study has some limitations. First, its sample size was small, and the normal concentration of PAPP-A and CD40 in the plasma of healthy individuals is mandatory when considering the protein as a biomarker, which still needs further study with a large sample size. Second, subjects with carotid artery stenosis were not included in the current study. Further studies to investigate whether the PPAP-A and CD40 would serve as predictors for vulnerable carotid plaque are warranted. Moreover, whether the plasma biomarkers for intracranial vulnerable plaques differ from those of carotid plaques remains to be elucidated.

In summary, PAPP-A and CD40 might sever as biomarkers for vulnerable plaque of MCAS. This preliminary finding requires validation in future studies.

Competing interests

The authors declare no competing interests.

Acknowledgements

The work was supported by grants from the technology development project of Jilin Province (No. 20170623092TC).
Plasma Pregnancy-Associated Plasma Protein A and CD40 are Potential Biomarkers of Vulnerable Plaque Associated with Middle Cerebral Artery Stenosis

References


Research